Bonspri 20 mg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Bonspri 20 mg Injection contains ocrelizumab, an anti-CD20 monoclonal antibody. Its labelling describes it as a treatment for relapsing forms of multiple sclerosis, acting by targeting and depleting certain B cells (a type of white blood cell) described as contributing to nerve damage in the disease.
Product Information
The following description reflects information associated with ocrelizumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of relapsing forms of multiple sclerosis
- Described as targeting and depleting CD20-positive B cells
- Described as reducing the frequency of relapses and slowing progression of disability when used as prescribed
Described Dosage & Administration
- Administered only by a healthcare professional as an intravenous infusion — not self-administered
- Given on the schedule set by the treating specialist; doses should not be missed
- Vaccinations are described as needing to be brought up to date before treatment begins
Described Side Effects
Commonly described side effects include:
- Infusion-related reactions (e.g. itching, rash, flushing, throat irritation)
- Fever, headache and chills
- Fatigue
- Upper respiratory tract infections
- Urinary tract infections
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Described as lowering immune cell counts, which may increase the risk of infections
- Screening for hepatitis B is described as necessary before treatment, as reactivation has been reported
- Patients with a weakened immune system or a history of hepatitis B should discuss this with the doctor first
- Effective contraception is described as necessary during and for a period after treatment
- Pregnancy or breastfeeding should be discussed with the prescriber
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains ocrelizumab and is described for relapsing forms of multiple sclerosis, acting on CD20-positive B cells. SDO Pharma has not independently verified these claims.
No. Its labelling states the infusion must be given by a healthcare professional in a setting equipped to manage infusion reactions.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.